Sabine Gilch

Prion-protein-specific aptamer reduces PrPSc formation.

Essential role of the prion protein N terminus in subcellular trafficking and half-life of cellular prion protein.

Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells.

Promising developments bringing prion diseases closer to therapy and prophylaxis.

Prion diseases: from molecular biology to intervention strategies.

Recognition of lumenal prion protein aggregates by post-ER quality control mechanisms is mediated by the preoctarepeat region of PrP.

The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.

The prion protein requires cholesterol for cell surface localization.

Prion infection influences murine endogenous retrovirus expression in neuronal cells.

Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrP( Sc ) propagation in prion-infected cells.

Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.

Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.

Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation.

The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery.

CpG and LPS can interfere negatively with prion clearance in macrophage and microglial cells.

Cell type-specific cleavage of nucleocapsid protein by effector caspases during SARS coronavirus infection.

Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc.

Targeting prion proteins in neurodegenerative disease.

Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice.

Autophagy induction by trehalose counteracts cellular prion infection.

Therapy in prion diseases: from molecular and cellular biology to therapeutic targets.

Aptamers against prion proteins and prions.

Prion-induced activation of cholesterogenic gene expression by Srebp2 in neuronal cells.

Inhibition of cholesterol recycling impairs cellular PrP(Sc) propagation.

Prion protein interaction with stress-inducible protein 1 enhances neuronal protein synthesis via mTOR.

Chronic wasting disease.

Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein.

Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain.

Failure of prion protein oxidative folding guides the formation of toxic transmembrane forms.

A genome-wide survey for prion-regulated miRNAs associated with cholesterol homeostasis.

Early detection of chronic wasting disease prions in urine of pre-symptomatic deer by real-time quaking-induced conversion assay.

Assessing proteinase K resistance of fish prion proteins in a scrapie-infected mouse neuroblastoma cell line.

Cholesterol balance in prion diseases and Alzheimer's disease.

Prion infection impairs lysosomal degradation capacity by interfering with rab7 membrane attachment in neuronal cells.

Early and Non-Invasive Detection of Chronic Wasting Disease Prions in Elk Feces by Real-Time Quaking Induced Conversion.

High prevalence of prion protein genotype associated with resistance to chronic wasting disease in one Alberta woodland caribou population.

Destabilizing polymorphism in cervid prion protein hydrophobic core determines prion conformation and conversion efficiency.